Abstract
Based on the improved understanding of cell and molecular biology of periodontal wound healing, the recombinant technology comprising rh growth factors and carrier construct is applied in periodontal regeneration. In 1997, the first recombinant (that is, synthetic) protein therapeutic agent was approved by the US Food and Drug Administration (FDA). In this paper we review the two commercially available recombinant agents, that is, rhPDGF-BB and rh-BMP-2 used for periodontal regeneration.
Key words: Periodontal regeneration, recombinant proteins, gene, tissue regeneration.
Copyright © 2025 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
